Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Baricitinib in Atopic Dermatitis (BREEZE-AD3)
NCT03334435Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (12 arms), sponsored by Eli Lilly and Company. Primary endpoint: Investigator's Global Assessment Response 0 or 1 at 52 weeks. Started Mar 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03334435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334435.